Company Filing History:
Years Active: 2025
Title: Kei Enomoto: Innovator in Antibody-Drug Conjugate Technology
Introduction
Kei Enomoto is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medical technology, particularly in the development of methods for identifying suitable candidates for antibody-drug conjugate therapies.
Latest Patents
Enomoto holds a patent for a "Sensitivity marker for antibody-drug conjugate." This innovative method involves identifying human patients suffering from cancer who are suitable for treatment with a medicament containing an anti-hTROP2 antibody. The process includes obtaining a biological sample from the patient, evaluating the expression levels of the hTROP2 and SLFN11 genes, and determining the appropriateness of the treatment based on these evaluations.
Career Highlights
Kei Enomoto is currently employed at Daiichi Sankyo Company, Limited, where he continues to advance his research and development efforts. His work focuses on improving cancer treatment methodologies through innovative approaches.
Collaborations
Enomoto collaborates with esteemed colleagues, including Daisuke Okajima and Satoru Yasuda, to enhance the effectiveness of their research and development projects.
Conclusion
Kei Enomoto's contributions to the field of antibody-drug conjugates exemplify the impact of innovative thinking in medical science. His work not only advances cancer treatment but also highlights the importance of collaboration in research.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.